Canopy Growth Corporation (CGC, Financial) experienced a significant stock price increase of 5.08%, trading at $2.07 per share with a trading volume of 4.41784 million shares. The stock's turnover rate was 3.61%, and it showed a price fluctuation amplitude of 5.84%.
Recent financial reports revealed the company generated $46.18 million in revenue, with a net loss of $96.45 million, translating to an earnings per share (EPS) of -$1.08. The gross profit stood at $11.60 million, resulting in a price-to-earnings ratio of -0.44.
Analyst ratings for Canopy Growth show a mixed outlook: 11% of participating firms recommend buying, 44% suggest holding, and 45% advise selling. Within the broader pharmaceutical industry, where Canopy Growth is categorized, the overall sector saw a 0.91% increase.
Other actively traded stocks in the sector included Quantum Biopharma Ltd., Cumberland Pharmaceuticals, and Incannex Healthcare Inc. Quantum Biopharma Ltd. was particularly notable with a turnover rate of 3178.15% and a price fluctuation of 62.58%.
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medical and recreational cannabis through brands like Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include Martha Stewart CBD skincare and Storz & Bickel vaporizers. The company has consolidated its U.S. assets into a separate holding entity, Canopy USA, which operates independently of its Canadian financials.
